Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma (NCT01703949)
This pilot clinical trial studies brentuximab vedotin in treating patients with relapsed or refractory cluster of differentiation 30+ (CD30+) lymphoma. Biological therapies, such as brentuximab vedotin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Condition: Relapsed or Refractory CD30+ Lymphoma
- Estimated Enrollment: 20
- Start: March 2013
- Estimated Primary Completion: June 2015
- Last verified: March 2015
Last Editorial review: July 20, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.